Beta-lactam antibiotic with beta-lactamase inhibitor

This page covers all Beta-lactam antibiotic with beta-lactamase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Penicillin-binding proteins (PBPs); bacterial beta-lactamase, Bacterial penicillin-binding proteins (PBPs); beta-lactamase enzymes, Penicillin-binding proteins (PBPs); bacterial beta-lactamases.

Targets

Penicillin-binding proteins (PBPs); bacterial beta-lactamase · Bacterial penicillin-binding proteins (PBPs); beta-lactamase enzymes · Penicillin-binding proteins (PBPs); bacterial beta-lactamases · Bacterial penicillin-binding proteins; beta-lactamases · Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam) · Penicillin-binding proteins; bacterial beta-lactamase enzymes · Penicillin-binding proteins (PBPs); beta-lactamase · Penicillin-binding proteins (PBPs); beta-lactamases · Penicillin-binding proteins (PBPs); beta-lactamase enzymes · Bacterial penicillin-binding proteins (PBPs); bacterial beta-lactamases

Marketed (19)

• Augmentin (ES)-600 · GlaxoSmithKline · Infectious Disease
  Augmentin ES-600 is a combination antibiotic that inhibits bacterial cell wall synthesis by blocking penicillin-binding proteins, with enhanced coverage against beta-lactamase-producing organisms.
• Augmentin® · Teva Pharmaceuticals USA · Infectious Disease
  Augmentin combines amoxicillin (a beta-lactam antibiotic) with clavulanic acid (a beta-lactamase inhibitor) to kill bacteria and overcome antibiotic resistance.
• Amoxicillin clavulanic · Hospital Italiano de Buenos Aires · Infectious Disease
  Amoxicillin-clavulanic acid is a combination antibiotic that kills bacteria by inhibiting cell wall synthesis, with clavulanic acid protecting amoxicillin from enzymatic degradation by beta-lactamases.
• cefoperazone sodium and sulbactam sodium · Yung Shin Pharm. Ind. Co., Ltd. · Infectious Disease
  Cefoperazone sodium inhibits bacterial cell wall synthesis while sulbactam sodium protects the antibiotic from beta-lactamase degradation, together providing broad-spectrum bactericidal activity.
• Imipenem+Relebactam · Wake Forest University Health Sciences · Infectious Disease
  Imipenem is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while relebactam is a beta-lactamase inhibitor that protects imipenem from enzymatic degradation by resistant bacteria.
• Amoxicillin and Clavulanic Acid · Maggiore Bellaria Hospital, Bologna · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from degradation by bacterial beta-lactamases.
• Piperacillin / Tazobactam Injection · Rambam Health Care Campus · Infectious Disease
  Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing the antibiotic to overcome resistance.
• high dose amoxicillin/clavulanate · Albany Medical College · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes to prevent antibiotic degradation.
• Piperacillin-tazobactam combination product · Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva · Infectious Disease
  Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
• Piperacillin-tazobactam · University Hospital, Bordeaux · Infectious Disease
  Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
• ampicillin/clavulanate · Phoenix Children's Hospital · Infectious Disease
  Ampicillin inhibits bacterial cell wall synthesis while clavulanate protects ampicillin from degradation by bacterial beta-lactamases.
• standard dose amoxicillin/clavulanate · Albany Medical College · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes that would otherwise destroy amoxicillin.
• Amoxycillin/clavulanic acid · TASK Applied Science · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes.
• Ampicillin / sulbactam · Medical University of Vienna · Infectious Disease
  Ampicillin inhibits bacterial cell wall synthesis while sulbactam inhibits bacterial beta-lactamase enzymes, together restoring ampicillin's activity against beta-lactamase-producing bacteria.
• Piperacillin, Tazobactam Drug Combination · Phoenix Children's Hospital · Infectious Disease
  Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing piperacillin to kill a broader spectrum of bacteria including beta-lactamase-producing organisms.
• amoxicillin/clavulanate potassium 1gm · GlaxoSmithKline · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin.
• Co-amoxiclav · Imperial College London · Infectious Disease
  Co-amoxiclav is a combination antibiotic that kills bacteria by inhibiting cell wall synthesis (amoxicillin) while protecting the amoxicillin from enzymatic degradation (clavulanic acid).
• Amoxicillin potassium clavulanate · Kaizen Bioscience Co. · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from degradation by bacterial beta-lactamases, extending its spectrum of activity.
• Amoxicillin-Potassium Clavulanate Combination · Universidad Complutense de Madrid · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis while potassium clavulanate protects amoxicillin from degradation by bacterial beta-lactamases, extending its spectrum of activity.

Phase 3 pipeline (7)

• Amoxicillin/clavulinic acid · Pfizer · Infectious Disease
  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes.
• Meropenem and Pralurbactam · Qilu Pharmaceutical Co., Ltd. · Infectious Disease
  Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria.
• Amoxicilline/clavulanic · Bayer · Infectious Disease
  Amoxicillin/clavulanic acid is a beta-lactam antibiotic combination that kills bacteria by inhibiting cell wall synthesis, with clavulanic acid protecting amoxicillin from degradation by bacterial beta-lactamases.
• One dose of Cefo-perazone Sulbactum · Asian Institute of Gastroenterology, India · Infectious Disease
  Cefoperazone/sulbactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.
• Administration of Amoxicillin / clavulanic acid · Medical University of Vienna · Infectious Disease
  Amoxicillin/clavulanic acid is a beta-lactam antibiotic combination that inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from beta-lactamase degradation.
• Sulbactam Sodium/Ampicillin Sodium · Pfizer · Infectious Disease
  Sulbactam inhibits bacterial beta-lactamases while ampicillin inhibits bacterial cell wall synthesis, together providing broad-spectrum bactericidal activity against beta-lactamase-producing organisms.
• Amoxicillin/clavulunate potassium · Merck Sharp & Dohme LLC · Infectious Disease
  Amoxicillin/clavulanate is a beta-lactam antibiotic combination that kills bacteria by inhibiting cell wall synthesis, with clavulanate protecting amoxicillin from degradation by bacterial beta-lactamases.